Repeated Implantation Failure
Conditions
Keywords
atosiban, clinical pregnancy, implantation rate, uterine contractility, IVF-ET
Brief summary
Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).
Detailed description
Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
Interventions
DRUGatosiban
Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Sponsors
Vietnam National University
An Sinh Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* had repeated implantation failure * have at least 1 good quality embryo for transfer
Exclusion criteria
* uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy | 5 weeks after intervention |
Countries
Vietnam
Outcome results
None listed